Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Week in Review: D3 Bio Raises $62 Million for Trials of KRAS G12C Inhibitor

publication date: Apr 13, 2024

Deals and Financings

  • D3 Bio of Shanghai closed a $62 million Series A+ financing round to conduct global trials of a KRAS G12C inhibitor and ramp up development of its preclinical assets;
  • Sino Biopharm formed a strategic partnership with Germany’s Boehringer Ingelheim to develop Boehringer 's innovative oncology pipeline in mainland China;
  • Suzhou Transcenta partnered with California’s Agilent Technologies to develop a companion diagnostic for Osemitamab, a Claudin18.2 mAb;

Trials and Approvals

  • Shanghai Junshi Biosciences was approved to market a combination of toripalimab and axitinib as a first-line treatment for advanced renal cell;
  • Hangzhou Jiuyuan Gene Engineering filed for approval of their biosimilar to Novo Nordisk’s Ozempic (semaglutide), a weight loss drug;
  • Beijing’s YS Biopharma reported positive results from the ongoing Phase III clinical trial of its next-gen PIKA Rabies Vaccine;
  • Shenzhen Kexing Biopharm started a Phase III clinical trial of an inhaled Interferon aIb therapy for respiratory syncytial virus infections in children;
  • Shanghai Abbisko Therapeutics has completed patient enrollment for a global Phase III trial of pimicotinib in patients with tenosynovial giant cell tumor;
  • Sichuan Kelun-Biotech and Merck reported early Phase I/II data showing their TROP2-directed ADC produced a promising disease control rate;
  • Suzhou VesiCURE Therapeutics reports its mesenchymal stem cell-derived extracellular vesicles showed efficacy in a mouse model of ulcerative colitis.

    Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital